華數傳媒(000156.SZ)發行股份及支付現金購買資產暨關聯交易獲浙江省財政廳批覆
格隆匯6月5日丨華數傳媒(000156.SZ)公佈,公司正在籌劃發行股份及支付現金購買浙江華數廣電網絡股份有限公司及寧波華數廣電網絡有限公司股權事項。2020年6月4日,公司收到控股股東華數數字電視傳媒集團有限公司轉來的《浙江省財政廳關於華數集團持有的浙江華數、寧波華數股權置入上市公司方案的批覆》(浙財文〔2020〕18號):經省文資委研究,原則同意華數集團持有的浙江華數、寧波華數股權置入上市公司重大資產重組方案。
此次交易事項尚需履行公司股東大會、中國證券監督管理委員會批准或核准等程序,本次交易事項能否取得前述批准或核准以及最終取得批准或核准的時間存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.